In silico studies for the rational discovery of anticonvulsant compounds.

Theoretical models to virtual screening and rational design of anticonvulsant compounds based on a topological substructural molecular design (TOSS-MODE) approach are developed. These models, developed on the basis of data sets of great structural variability, permit the classification of compounds as active/inactive anticonvulsants and predict the quantitative anticonvulsant potency of such compounds. The classification model is applied to a virtual screening of anticonvulsant compounds by analyzing a data set of molecules reported in the literature. More than 88% of them were well classified by the current model. Active and inactive fragments are identified by using the present approach. Some of the active fragments are identified in anticonvulsant molecules as potential pharmacophores and one of them is analyzed in detail. The three-dimensional (3-D) features of this fragment are investigated in a series of five anticonvulsant compounds. Some structure-anticonvulsant activity relationships are derived on the basis of the 3-D structure of this fragment and some findings reported in the literature that indicate that it is an important pharamacophore are outlined.

[1]  M. Wagner Felbamate: a new antiepileptic drug. , 1994, American journal of hospital pharmacy.

[2]  J. Stables,et al.  Synthesis of 2-piperidinecarboxylic acid derivatives as potential anticonvulsants , 1998 .

[3]  J. Stewart Optimization of parameters for semiempirical methods I. Method , 1989 .

[4]  E. Gordon,et al.  Combinatorial chemistry and molecular diversity in drug discovery , 1998 .

[5]  M. Brodie,et al.  Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy , 1995, The Lancet.

[6]  Ernesto Estrada,et al.  Spectral Moments of the Edge Adjacency Matrix in Molecular Graphs, 1. Definition and Applications to the Prediction of Physical Properties of Alkanes , 1996, J. Chem. Inf. Comput. Sci..

[7]  Peter Welling The Drug Development Process : Increasing Efficiency and Cost-Effectiveness , 1996 .

[8]  E. Perucca,et al.  The new generation of antiepileptic drugs: advantages and disadvantages. , 1996, British journal of clinical pharmacology.

[9]  J. Stables,et al.  Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives. , 1996, Journal of medicinal chemistry.

[10]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[11]  N. Cosford,et al.  Chapter 7 - Recent Progress In Antiepileptic Drug Research , 1998 .

[12]  Alexandru T. Balaban,et al.  From chemical topology to three-dimensional geometry , 2002 .

[13]  J. Quail,et al.  (Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. , 1996, Journal of medicinal chemistry.

[14]  Isa,et al.  Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives , 1998, Journal of medicinal chemistry.

[15]  Ernesto Estrada,et al.  A novel approach for the virtual screening and rational design of anticancer compounds. , 2000, Journal of medicinal chemistry.

[16]  K. Tipton,et al.  Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase. , 1994, Biochemical pharmacology.

[17]  Ernesto Estrada,et al.  Edge Adjacency Relationships and a Novel Topological Index Related to Molecular Volume , 1995, J. Chem. Inf. Comput. Sci..

[18]  F. Popp,et al.  Potential anticonvulsants IV: Condensation of isatin with benzoylacetone and isopropyl methyl ketone. , 1982, Journal of pharmaceutical sciences.

[19]  C. Rundfeldt,et al.  D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. , 1996, European journal of pharmacology.

[20]  J. Poupaert,et al.  Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. , 1998, Journal of medicinal chemistry.

[21]  J. Quail,et al.  Anticonvulsant activity of various aryl, arylidene and aryloxyaryl semicarbazones , 1998 .

[22]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[23]  S. Mignani,et al.  Riluzole series. Synthesis and in vivo "antiglutamate" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. , 1999, Journal of medicinal chemistry.

[24]  A. Crider,et al.  Synthesis and anticonvulsant activity of racemic 2-amino-N-substituted succinimide derivatives. , 1981, Journal of pharmaceutical sciences.

[25]  Ernesto Estrada,et al.  Spectral Moments of the Edge-Adjacency Matrix of Molecular Graphs, 2. Molecules Containing Heteroatoms and QSAR Applications , 1997, J. Chem. Inf. Comput. Sci..

[26]  P. Pevarello,et al.  Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. , 1998, Journal of medicinal chemistry.

[27]  E. Perucca,et al.  Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference , 1996, Epilepsy Research.

[28]  P. Lehmann,et al.  Partition coefficients of three new anticonvulsants. , 1990, Journal of pharmaceutical sciences.

[29]  C. Elger,et al.  New Antiepileptic Drugs in Epileptology , 1998, Neuropsychobiology.

[30]  B. Cooper,et al.  1-(Fluorobenzyl)-4-amino-1H-1,2,3-triazolo[4,5-c]pyridines: synthesis and anticonvulsant activity. , 1995, Journal of medicinal chemistry.

[31]  C. M. Darling,et al.  Anticonvulsant activity of alkyl-substituted N-benzylcyanoacetamides. , 1979, Journal of pharmaceutical sciences.

[32]  M. Bialer,et al.  Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. , 1990, Journal of pharmaceutical sciences.

[33]  Ramón García-Domenech,et al.  Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach , 1998, Journal of computer-aided molecular design.

[34]  E. Lunney,et al.  Transport of Gabapentin, a γ‐Amino Acid Drug, by System L α‐Amino Acid Transporters: A Comparative Study in Astrocytes, Synaptosomes, and CHO Cells , 1995 .

[35]  J. Penry,et al.  Antiepileptic Drug Development: I. History and a Program for Progress , 1978, Epilepsia.

[36]  Ernesto Estrada,et al.  Spectral Moments of the Edge Adjacency Matrix in Molecular Graphs. 3. Molecules Containing Cycles , 1998, J. Chem. Inf. Comput. Sci..

[37]  W. Löscher,et al.  Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? , 1994, Epilepsy Research.

[38]  P. Patsalos New Antiepileptic Drugs , 1999, Annals of clinical biochemistry.

[39]  J. Korf,et al.  Effect of milacemide, a glycinamide derivative, on the rat brain gamma-aminobutyric acid system. , 1983, Biochemical pharmacology.

[40]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[41]  J. Gobert,et al.  ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. , 1992, European journal of pharmacology.

[42]  H. Lankau,et al.  Synthesis, anticonvulsant activity, and structure-activity relationships of sodium channel blocking 3-aminopyrroles. , 1998, Journal of medicinal chemistry.

[43]  F. Popp,et al.  Potential anticonvulsants VI: condensation of isatins with cyclohexanone and other cyclic ketones. , 1983, Journal of pharmaceutical sciences.

[44]  M A Rogawski,et al.  Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. , 1990, Pharmacological reviews.

[45]  B. Cooper,et al.  8-Amino-3-benzyl-1,2,4-triazolo[4,3-a]pyrazines. Synthesis and anticonvulsant activity. , 1995, Journal of medicinal chemistry.

[46]  E Estrada,et al.  Modeling chromatographic parameters by a novel graph theoretical sub-structural approach. , 1999, Journal of chromatography. A.

[47]  M. Youdim,et al.  Formation of the Neurotransmitter Glycine from the Anticonvulsant Milacemide Is Mediated by Brain Monoamine Oxidase B , 1988, Journal of neurochemistry.